Arcellx (ACLX) Q4 2025 earnings summary

Executive summary

• Clinical-stage biotech focused on innovative immunotherapies for cancer and incurable diseases, leveraging proprietary D-Domain technology to address limitations of traditional CAR-T therapies.

• Lead program anito-cel (BCMA-targeting ddCAR) in pivotal Phase 2 and 3 trials for relapsed/refractory multiple myeloma (rrMM), with additional programs in autoimmune and hematologic indications.

• Collaboration with Kite Pharma (Gilead) for co-development and commercialization of anito-cel and next-gen CAR-Ts; BLA for anito-cel accepted by FDA with PDUFA date of December 23, 2026.

• Pending acquisition by Gilead via tender offer and merger at $115/share plus $5 CVR, subject to milestone achievement.

Financial highlights

• Net loss of $228.9M for 2025, up from $107.3M in 2024, driven by increased R&D and G&A expenses.

• Collaboration revenue of $22.3M in 2025, down from $107.9M in 2024, reflecting completion of dosing in iMMagine-1 trial.

• R&D expenses stable at $157.6M in 2025; G&A expenses increased to $117.8M (up $29.3M year-over-year).

• Cash, cash equivalents, and marketable securities of $520.1M as of December 31, 2025; sufficient to fund operations into 2028.

Outlook and guidance

• Anticipates FDA decision on anito-cel by December 2026; plans to expand clinical programs in earlier lines of therapy and new indications.

• Expects continued operating losses and increased expenses as pipeline advances and commercial readiness activities ramp up.

• Gilead acquisition expected to close in Q2 2026, subject to customary conditions.